Abstract: Compositions and methods for treating or preventing nonalcoholic steatohepatitis (NASH) fibrosis, also known as MASH. In one aspect, the disclosed methods relate to targeting a MBOAT7 risk variant, rs641738, in order to increase MBOAT7 expression and down-stream signaling or to silence TAZ. The compositions and methods disclosed herein can be used as disease modifying therapies to enable treatment of NASH fibrosis/MASH and related disorders earlier in disease progression and improve clinical outcomes.

Abstract: A lightweight concrete composition containing from 10 to 90 volume percent of a cement composition, from 10 to 90 volume percent of particles having an average particle diameter of from 0.2 mm to 8 mm, a bulk density of from 0.03 g/cc to 0.64 g/cc, an aspect ratio of from 1 to 3, and from 0 to 50 volume percent of aggregate; where the sum of components used does not exceed 100 volume percent, and where after the lightweight concrete composition is set it has a compressive strength of at least 1700 psi as tested according to ASTM C39 after seven days. The concrete composition can be used to make concrete masonry units, construction panels, road beds and other articles.

Abstract: A lightweight cementitious composition containing from 10 to 90 volume percent of a cement composition, from 10 to 90 volume percent of particles having an average particle diameter of from 0.2 mm to 8 mm, a bulk density of from 0.03 g/cc to 0.64 g/cc, an aspect ratio of from 1 to 3, and from 10 to 50 volume percent of sand and/or other fine aggregate, where at least a portion of the sand and/or fine aggregate has a fineness modulus of less than 2; where the sum of components used does not exceed 100 volume percent, and where after the lightweight cementitious composition is set it has a compressive strength of at least 1700 psi as tested according to ASTM C39 after seven days. The cementitious composition can be used to make concrete masonry units, construction panels, road beds and other articles.

Abstract: The present invention provides disaccharide and trisaccharide C6 to C12 mixed fatty acid esters having a high alpha content. Yet still further, the invention provides chemical processes for the preparation of the materials disclosed herein.